BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Santander Ballestín S, Gómez Martín D, Lorente Pérez S, Luesma Bartolomé MJ. Hepatitis C: A Pharmacological Therapeutic Update. J Clin Med 2021;10:1568. [PMID: 33917830 DOI: 10.3390/jcm10081568] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Glombicki SE, Cohen PR. Sofosbuvir-Velpatasvir (Epclusa)-Associated Photosensitivity in a Hepatitis C Patient: Case Report and Review of Photosensitivity to Hepatitis C Antiviral Agents. Cureus 2021;13:e16496. [PMID: 34430111 DOI: 10.7759/cureus.16496] [Reference Citation Analysis]
2 Abu-Freha N, Mathew Jacob B, Elhoashla A, Afawi Z, Abu-Hammad T, Elsana F, Paz S, Etzion O. Chronic hepatitis C: Diagnosis and treatment made easy. Eur J Gen Pract 2022;28:102-8. [PMID: 35579223 DOI: 10.1080/13814788.2022.2056161] [Reference Citation Analysis]
3 Zhang GN, Zhao J, Li Q, Wang M, Zhu M, Wang J, Cen S, Wang Y. Discovery and optimization of 2-((1H-indol-3-yl)thio)-N-benzyl-acetamides as novel SARS-CoV-2 RdRp inhibitors. Eur J Med Chem 2021;223:113622. [PMID: 34147744 DOI: 10.1016/j.ejmech.2021.113622] [Reference Citation Analysis]
4 Yan D, Ra OH, Yan B. The nucleoside antiviral prodrug remdesivir in treating COVID-19 and beyond with interspecies significance. Anim Dis 2021;1:15. [PMID: 34778881 DOI: 10.1186/s44149-021-00017-5] [Reference Citation Analysis]